The present invention provides a novel crystalline form of Ribociclibsuccinate,Ribociclib succinate Form APO-I, comprising Ribociclib succinate, benzylalcoholand water, compositions thereof, processes for the preparation thereof, andtheuse of this crystalline form in the treatment of conditions associated withincreasedCDK4/6 kinase activity, and in particular, cancers, including certain forms ofbreastcancer.
